Icosavax to Participate in Upcoming Investor Conferences
November 11 2021 - 4:22PM
Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company
leveraging its innovative virus-like particle (VLP) platform
technology to develop vaccines against infectious diseases, with an
initial focus on life-threatening respiratory diseases, today
announced that Adam Simpson, Chief Executive Officer of Icosavax,
will participate in two upcoming investor conferences.
Details of the events are below:
- Jefferies London Healthcare Conference:
Icosavax will participate in a fireside chat that will be available
at 3:00 AM ET on Thursday, November 18, 2021.
- Evercore ISI 4th
Annual HealthCONx Virtual Conference: Icosavax
will participate in a fireside chat on Thursday, December 2, 2021,
at 4:20 PM ET.
The webcasts of the Jefferies London fireside
chat and the Evercore ISI fireside chat will be available on the
Events page of the Investor Relations section of Icosavax’s
website, ir.icosavax.com. The webcast replays will be available on
the website for approximately 30 days.
About Icosavax
Icosavax is a biopharmaceutical company
leveraging its innovative VLP platform technology to develop
vaccines against infectious diseases, with an initial focus on
life-threatening respiratory diseases. Icosavax’s VLP platform
technology is designed to enable multivalent, particle-based
display of complex viral antigens, which it believes will induce
broad, robust, and durable protection against the specific viruses
targeted. Icosavax’s pipeline includes vaccine
candidates targeting respiratory syncytial virus (RSV), human
metapneumovirus (hMPV), and severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017
to advance the breakthrough VLP technology from the Institute for
Protein Design at the University of Washington with the goal to
discover, develop, and commercialize vaccines against infectious
diseases. Icosavax exclusively licensed the VLP
technology for use in several fields, including RSV and hMPV, from
the University of Washington. For
SARS-CoV-2, Icosavax has a non-exclusive, worldwide
(excluding South Korea) license from the University of Washington
that will convert to an exclusive license in North America and
Europe in 2025. Icosavax is located in Seattle.
Forward-Looking Statements
Statements by the company regarding matters that
are not historical facts are forward-looking statements. The
forward-looking statements are based on the company’s current
beliefs and expectations and include, but are not limited to: the
company’s expectation regarding the opportunities for, and the
therapeutic and commercial potential of, its vaccine product
candidates; the company’s ability to advance its development
program and achieve the noted development milestones in 2022; and
the sufficiency of the company’s current cash, cash equivalents,
and investments to fund its operations through at least 2024.
Actual results may differ from the forward-looking statements due
to the risks and uncertainties inherent in the company’s business,
including, without limitation: the early stage of the company’s
development efforts; the company’s approach to the development of
vaccine candidates, including its plan to pursue a combination
bivalent RSV/hMPV VLP vaccine candidate, which is a novel and
unproven approach; potential delays in the commencement,
enrollment, and completion of clinical trials and preclinical
studies; the company’s dependence on third parties in connection
with manufacturing, research, and preclinical and clinical testing;
unexpected adverse side effects or inadequate efficacy of the
company’s product candidates that may limit their development,
regulatory approval, and/or commercialization; results from
preclinical studies or early clinical trials not necessarily being
predictive of future results; competing approaches limiting the
commercial value of the company’s vaccine candidates; regulatory
developments in the United States and other countries; the
company’s ability to obtain and maintain intellectual property
protection for its product candidates and maintain its rights under
intellectual property licenses; the company’s ability to fund its
operating plans with its current cash, cash equivalents, and
investments; the company’s ability to maintain undisrupted business
operations during the COVID-19 pandemic, including with respect to
clinical trials, manufacturing, and supply chain; and other risks
described in the company’s prior filings with the Securities and
Exchange Commission (SEC), including under the heading “Risk
Factors” in the company’s quarterly report on Form 10-Q for the
quarter ended June 30, 2021 and any subsequent filings with the
SEC. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made, and the company undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after such date. All forward-looking statements are qualified in
their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Media Contact: Jessica
Yingling, Ph.D.Little Dog Communications
Inc.jessica@litldog.com+1.858.344.8091
Investor Contact: Laurence
WattsGilmartin Group,
LLClaurence@gilmartinir.com+1.619.916.7620
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Apr 2023 to Apr 2024